questionText: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of NICE's severity modifier on the availability of Enhertu for patients with secondary breast cancer.
answerText: The National Institute for Health and Care Excellence (NICE) considered the impact of its severity modifier as part of its appraisal of Enhertu for HER2-low metastatic breast cancer. However, even with the severity weighting applied, NICE concluded that t...
heading: Trastuzumab Deruxtecan